Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device, Drug Import Safety Legislation Resurfaces

This article was originally published in The Gray Sheet

Executive Summary

The House will likely consider device and drug import safety legislation in the near term, according to lawmakers and Hill staffers

You may also be interested in...



Senate Crafts Import Safety Bill, As Device Reps Prep For House Hearing

Sen. Ted Kennedy, D-Mass., is crafting a bill to strengthen FDA's oversight of products manufactured overseas, including devices

Draft House Bill Seeks To Strengthen FDA’s Role In Device Import Safety

Leading House Democrats plan to expedite legislation that would give FDA new powers to collect facility registration fees to support foreign device inspection costs and greater authority to fine companies that violate import rules

Sun Denied Over US Antitrust Challenge

India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.

Topics

UsernamePublicRestriction

Register

MT028812

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel